Archived Monthly Oncology Tumor Boards: Management of Early-Stage Non-Small Cell Lung Cancer

Health care providers need to know about the recent updates to the NCCN Guidelines® for Non-Small Cell Lung Cancer to provide the best care for their patients with NSCLC, including adverse reactions that may occur with use of the new neoadjuvant and adjuvant systemic therapy regimens.

Target Audience

This activity is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Identify the new neoadjuvant and adjuvant systemic therapy regimens for patients with resectable non-small cell lung cancer (NSCLC).
  • Describe the adverse reactions that may occur with the new neoadjuvant and adjuvant systemic therapy regimens.
  • Discuss strategies to educate patients about the new neoadjuvant and adjuvant systemic therapy regimens that are available for those with resectable NSCLC.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca, GSK, Lantheus, and Novartis. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
02/27/2024
Course expires: 
02/27/2025
Cost:
$0.00
Part of: 
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care

Thomas Ng, MD
The University of Tennessee Health Science Center

Jason Porter, MD
West Cancer Center & Research Institute

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no financial relationships with ineligible companies to disclose.

Thomas Ng, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jason Porter, MD
Amgen Inc.: Consulting Fee; Product/Speakers Bureau
AstraZeneca Pharmaceuticals LP: Consulting Fee; Honoraria
Boehringer Ingelheim GmbH: Consulting Fee
Bristol Myers Squibb: Consulting Fee; Honoraria; Product/Speakers Bureau
Daiichi-Sankyo Co.: Consulting Fee; Honoraria
EMD Serono: Consulting Fee; Honoraria; Product/Speakers Bureau
Genentech, Inc.: Consulting Fee; Honoraria; Product/Speakers Bureau
Janssen Pharmaceutica Products, LP: Consulting Fee; Honoraria; Product/Speakers Bureau
Jazz Pharmaceuticals Inc.: Consulting Fee; Honoraria; Product/Speakers Bureau
Merck & Co., Inc: Consulting Fee; Honoraria; Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Consulting Fee; Honoraria
Regeneron Pharmaceuticals: Consulting Fee; Honoraria; Product/Speakers Bureau
Takeda Pharmaceuticals North America, Inc.: Consulting Fee; Honoraria

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-020-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until February 27, 2025. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: I00058277; Approval #: 240000349

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing